Cutaneous T-cell Lymphoma  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

8 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cutaneous T-cell Lymphoma
NCT01196208 / 2010-020363-21: A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

No Longer Available
N/A
Europe, US, RoW
brentuximab vedotin, SGN-35
Seagen Inc., Millennium Pharmaceuticals, Inc.
Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous
 
 
MK0683-042, NCT00419367 / 2006-003879-12: Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)

No Longer Available
N/A
NA
Comparator: vorinostat
Merck Sharp & Dohme LLC
Lymphoma, T-Cell, Cutaneous
 
 
GR-CTCL_CL, NCT06421571: The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients

Recruiting
N/A
40
Europe
National and Kapodistrian University of Athens, Recordati Rare Diseases
Mycosis Fungoides
02/25
12/25
NCT04014374: Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

Recruiting
N/A
150
US
Kyowa Kirin, Inc.
Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL
02/30
02/30
BELIEVE, NCT04998331: A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin

Active, not recruiting
N/A
51
Europe
No Intervention
Takeda
Hodgkin Disease, Lymphoma, T-Cell, Cutaneous
06/24
06/24
NCT05886478: A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin

Recruiting
N/A
50
Europe
No intervention
Takeda
T-Cell Lymphoma
06/24
06/24
PROSPER, NCT05455931: Real World Observational Study of Poteligeo in Adult Patients With MF and SS

Recruiting
N/A
80
Europe, US, RoW
Poteligeo, Mogamulizumab
Kyowa Kirin Pharmaceutical Development Ltd
Mycosis Fungoides and Sézary Syndrome
08/25
08/25
NCT05137847: A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Completed
N/A
118
Japan
Remitoro, Denileukin diftitox
Eisai Inc.
Lymphoma, T-cell, Peripheral, Lymphoma, T-cell, Cutaneous
03/23
03/23

Download Options